EPCAM and cancer: M6-Hh tumors had a higher proportion of CD61hi cells, previously shown to be a marker of mouse mammary CSCs15, within the EpCAM+CD24hiCD29+ cancer cell population (55.3% in M6-Hh tumors vs. 36.4% in M6-Ctrl  tumors; Fig. 1e).